Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the space of a few weeks, four articles appeared in the The Lancet and JAMA suggesting that using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) is associated with increased bone mineral density (BMD) and a reduced fracture risk. The stimulus for these case-control studies came from reports that the statins have unexpected effects on bone, increasing bone formation in rodents. These observations offered a new insight into the potential importance of the cholesterol synthesis pathway in bone turnover and future therapeutic opportunities.

Original publication

DOI

10.1007/s00223-001-2017-7

Type

Journal article

Journal

Calcified tissue international

Publication Date

08/2001

Volume

69

Pages

63 - 66

Addresses

The Kennedy Institute of Rheumatology, Imperial College School of Medicine, London, UK.

Keywords

Bone and Bones, Animals, Humans, Mevalonic Acid, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Bone Density